Vishnu Priya Pulipati
Endocrinology, Diabetes & Metabolism · Tulsa, OKNPI 1851774137
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,661 of the $7,596 with a category attached, or 61.4%. 30 manufacturers reported payments, led by Novo Nordisk at 30.7% of the total. Reporting peaked in 2019 at $2,055 and has fallen 60.7% since, to $808 in 2025.
Across 217 payments — averaging $35.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Merck$2K
- Dexcom, Inc.$539
- AstraZeneca$521
- Abbott$441
- Amgen$368
- plus $2K from 24 others
What the payments were for
- Consulting fees$1,52520%
- Travel & lodging$1,41019%
- Food & beverage$4,66161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $2,330 |
| Merck | 2 | $1,525 |
| Dexcom, Inc. | 33 | $539 |
| AstraZeneca(2 entities) | 22 | $521 |
| Abbott | 34 | $441 |
| Amgen(2 entities) | 16 | $368 |
| Boehringer Ingelheim | 17 | $289 |
| Lilly USA, LLC | 13 | $258 |
| Bayer | 7 | $222 |
| Esperion Therapeutics, Inc. | 3 | $165 |
| Sanofi-aventis U.S. LLC | 1 | $115 |
| Recordati_rare_diseases_inc. | 5 | $110 |
| Tandem Diabetes Care, Inc. | 4 | $95 |
| Xeris Pharmaceuticals, Inc. | 5 | $89 |
| Regeneron Healthcare Solutions, Inc. | 1 | $76 |
| Astellas Pharma US Inc | 2 | $58 |
| Mannkind Corporation | 3 | $57 |
| Ultragenyx Pharmaceutical Inc. | 2 | $48 |
| Corcept Therapeutics | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $40 |
| Amryt Pharma Holdings Ltd | 2 | $36 |
| Insulet Corporation | 2 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Medtronic | 1 | $18 |
| Cequr Corporation | 1 | $15 |
| AbbVie | 1 | $15 |
| BETA Bionics, Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Nevro Corp. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,596 in reported general payments places this provider in the 70th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 188 | $320,152 |
| TrulicityDulaglutide | 103 | $148,852 |
| MounjaroTirzepatide | 121 | $145,161 |
| JardianceEmpagliflozin | 76 | $121,679 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 36 | $113,565 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 74 | $109,512 |
| FarxigaDapagliflozin Propanediol | 92 | $97,507 |
| Tresiba Flextouch U-200Insulin Degludec | 47 | $66,873 |
| Tresiba Flextouch U-100Insulin Degludec | 74 | $59,679 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 94 | $53,123 |
| Novolog FlexpenInsulin Aspart | 90 | $32,216 |
| TymlosAbaloparatide | 12 | $30,587 |
| RybelsusSemaglutide | 25 | $29,506 |
| Humalog Kwikpen U-100Insulin Lispro | 56 | $24,928 |
| Repatha SureclickEvolocumab | 31 | $23,768 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,330 | $359,412237 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $258 | $294,013224 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $289 | $154,054101 claims |
| AstraZenecaFarxiga | $521 | $97,50792 claims |
| AbbVieSynthroid | $15 | $22,441264 claims |
| Sanofi-aventis U.S. LLCLantus | $115 | $3,28125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Tulsa
- Cristin BrunsTulsa$159K
- Donald AspensonTulsa$153K
- Hanna FoggTulsa$25K
- Mario Bustos RodriguezTulsa$19K
- Elie AbedTulsa$10K
- Maria VargasTulsa$7K
- Christian HansonTulsa$4K
- Miguel Jara PalaciosTulsa$4K
- Deepa PhilipTulsa$4K
- Alekya PolojuTulsa$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.